Patents Issued in May 1, 2018
  • Patent number: 9956252
    Abstract: Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF ? signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: May 1, 2018
    Assignee: TISSUETECH, INC.
    Inventors: Scheffer Tseng, Hua He, Wei Li
  • Patent number: 9956253
    Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: May 1, 2018
    Assignee: MiMedx Group, Inc.
    Inventor: John Daniel
  • Patent number: 9956254
    Abstract: The present invention provides a method for treating an ocular disease in a subject in need thereof, comprising administering an effective amount of an extract of Taiwanese propolis (TP) or an active component thereof to the subject. Also provided is a pharmaceutical composition for treating an ocular disease, which comprises an effective amount of an extract of TP or an active component thereof, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: May 1, 2018
    Assignee: NATUREWISE BIOTECH & MEDICALS CORPORATION
    Inventor: Chi Chou Liao
  • Patent number: 9956255
    Abstract: The present invention describes a method to reduce body weight, fat accumulation and adipocyte size by administering the probiotic bacterium Parabacteroides goldsteinii. This probiotic bacterium can therefore be used to treat obesity in animals and humans.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: May 1, 2018
    Assignee: CHANG GUNG BIOTECHNOLOGY CORP.
    Inventors: Yun-Fei Ko, Jan Martel, Tsung-Ru Wu, Chih-Jung Chang, Chuan-Sheng Lin, Jian-Ching Liau, Wei-Chang Wang, Chen-Yaw Chiu, Chia-Chen Lu, David Marcelo Ojcius, Hsin-Chih Lai, John D. Young
  • Patent number: 9956256
    Abstract: The present invention relates to a novel bacteriophage ?CJ26 (KCCM11464P) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by Salmonella by using the bacteriophage ?CJ26 (KCCM11464P) or the composition.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: May 1, 2018
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Eun Mi Shin, Bo Kyung Son, Gi Duk Bae, Jae Won Kim
  • Patent number: 9956257
    Abstract: Disclosed in certain embodiments is a canola extract comprising greater than 30% sinapic acid, pharmaceutical compositions thereof, and methods thereof.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: May 1, 2018
    Assignee: KGK Science, Inc.
    Inventors: Najla Guthrie, Robert Allen Guthrie
  • Patent number: 9956258
    Abstract: A drink includes an edible liquid or semisolid preparation and transfer factor. The drink may also include lactoferrin and one or more preservatives. An edible preparation includes a fruit component and transfer factor. The fruit component may include at least one oligoproanthocyanidin-containing fruit. The edible preparation may also include lactoferrin. One or more preservatives may also be included in the edible preparation. The drink or the edible preparation may be sterilized or pasteurized.
    Type: Grant
    Filed: May 2, 2006
    Date of Patent: May 1, 2018
    Assignee: 4Life Patents, LLC
    Inventors: Calvin W. McCausland, Brent Vaughan, David Lisonbee
  • Patent number: 9956259
    Abstract: The present invention relates to a pharmaceutical composition for preventing and treating obesity which comprises the green tea (Camellia sinensis L.) seed husk extract or the fraction thereof as an active ingredient. The green tea seed husk extract exhibits a significant vasculogenesis suppressing effect and has been confirmed to be effective in reducing adipocytes and body weight, and thus the green tea seed husk extract can advantageously be used as an active ingredient in a composition for preventing and treating obesity, a health food for preventing and alleviating obesity, or a pharmaceutical composition for vasculogenesis suppression.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: May 1, 2018
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventor: Jong Deog Kim
  • Patent number: 9956260
    Abstract: Provided herein are compositions and methods for the treatment of a patient having an HIV-1 infection and/or AIDS. More specifically this invention provides treatment of an HIV-1 infection and/or AIDS using small molecule compounds, such as inhibitors for the activation and/or activity of caspase-1. Inhibitors for the activation and/or activity of caspase-1 also prevent the cell death of CD4 T-cells in a population of CD4 T-cells comprising HIV-1 infected CD4 T-cells and uninfected CD4 T-cells, In addition, caspase-1 inhibitors inhibit inflammation, and pyroptosis.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: May 1, 2018
    Assignee: The J. David Gladstone Institutes
    Inventors: Warner C. Greene, Gilad Doitsh, Orlando Zepeda, Nicole Galloway
  • Patent number: 9956261
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: May 1, 2018
    Assignees: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Patent number: 9956262
    Abstract: The present invention relates to an isolated bacterium from the genus Pseudoalteromonas for its use as a probiotic, the use of said strain as a preservative, cyclolipopeptides which may be obtained from this bacterium, a composition comprising at least such a cyclolipopeptide, as well as to their uses.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: May 1, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE RENNES 1, UNIVERSITE DE BRETAGNE OCCIDENTALE
    Inventors: Florie Desriac, Yannick Fleury, Patrick Le Chevalier, Delphine Destoumieux, Matthieu Simon
  • Patent number: 9956263
    Abstract: Liposomal and/or nano-liposomal encapsulated HSP90a, HPf polypeptide (115 aa) and novel polypeptides HPf ?C1 (101 aa) and HPf?C2 (87 aa), as well as methods for manufacturing/preparing and using the compositions, are disclosed. Chimeric fusion proteins that include an HSP90a, HPf-polypeptide, HPf ?C1 or HPf?C2 polypeptide are presented. Transformed cell lines and expression vectors capable of expressing the chimeric fusion proteins, are provided. Methods for producing large amounts of recombinant HSP90a, HPf polypeptide, HPf ?C1 or HPf?C2 polypeptide, using expression vectors and transformed cell lines, are described. Topical and other delivery form preparations and methods for using the preparations, including methods for improving skin conditions (atopic dermatitis, wrinkles, skin elasticity, dark spots (over pigmentation), overall skin rejuvenation, skin ageing) for therapeutic and cosmeceutical uses are presented.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: May 1, 2018
    Assignee: REGERON, INC.
    Inventors: Kibum Nam, Kyunyoung Lee, Youngwook Cho, Dahlkyun Oh
  • Patent number: 9956264
    Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analog thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: May 1, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Allan C. Shaw, Charlotte Helgstrand, Michael P. Bastner Sandrini, Sebastian B. Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim V. Andersen
  • Patent number: 9956265
    Abstract: The present invention relates to a composition comprising erythropoietin (EPO) as an active ingredient for aiding surgical procedures for treating ischemic vascular diseases. The present invention also relates to a method for treating ischemic vascular diseases using a combination of the composition and the invasive procedure for sufficient disruption of the physical barriers for new neovascularization. The composition for aiding surgical or invasive procedures according to the present invention would be beneficial for the success rate and safety issue of a variety of surgical procedures such as minimally invasive operations performed on a patient suffering from a variety of cerebral ischemic vascular diseases including ischemic stroke and moyamoya disease, and can be widely used in the treatment of a variety of ischemic vasculopathies in cardiac or peripheral artery system.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: May 1, 2018
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventor: Ji Man Hong
  • Patent number: 9956266
    Abstract: The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: May 1, 2018
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Anthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
  • Patent number: 9956267
    Abstract: C-natriuretic peptide (CNP) has been shown to regulate proliferation of mouse and rat osteoblasts. Genetic deletion of CNP results in dwarfism. CNP effects on bone growth involve inhibition of MEK 1 and ERK 1/2 kinases mediated via the intracellular messenger cyclic GMP. Vessel dilator is another natriuretic peptide synthesized by the atrial natriuretic peptide gene whose biologic half-life is 12 times longer than CNP. Vessel dilator's biologic effects on proliferating cells are mediated via inhibiting MEK 1/2 and ERK 1/2 kinases via cyclic GMP. Vessel dilator was not studied previously on osteoblasts. CNP and vessel dilator were tested in dose-response studies enhanced human osteoblasts' proliferation, showing that vessel dilator has identical mechanisms of action to CNP but much longer biologic half-life and effects at lower concentrations. Vessel dilator exhibited therapeutic effect for use in human achondroplasia, short stature and osteoporosis by stimulating osteoblast proliferation.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: May 1, 2018
    Assignees: University of South Florida, United States Department of Veterans Affairs
    Inventor: David Lynn Vesely
  • Patent number: 9956268
    Abstract: The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of neuropeptide Y.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: May 1, 2018
    Inventor: Staley A. Brod
  • Patent number: 9956269
    Abstract: The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: May 1, 2018
    Assignee: CSL Limited
    Inventors: Carsten Horn, Sabine Zollner, Hubert Metzner, Stefan Schulte
  • Patent number: 9956270
    Abstract: The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity comprising a polypeptide comprising a bee venom-PLA2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase A2 of the present invention activates a regulatory T cell and suppress a differentiation of Th1/Th7. Therefore, the present polypeptide can be used as a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory T cell activity, i.e. autoimmune diseases, allergic diseases, or neurodegenerative diseases.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 1, 2018
    Assignee: INIST ST CO., LTD.
    Inventors: Hyun Su Bae, Hyo Jung Lee, Gi Hyun Lee, Hyun Seong Kim, Soo Jin Park, Eun Sook Chung, Tae Won Choi
  • Patent number: 9956271
    Abstract: Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification 5 conferring stability to the RNA, as well as related methods, are disclosed.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 1, 2018
    Assignee: TRANSLATE BIO, INC.
    Inventors: Braydon Charles Guild, Michael Heartlein, Frank DeRosa
  • Patent number: 9956272
    Abstract: Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: May 1, 2018
    Assignee: Bio Products Laboratory Limited
    Inventors: Joanne Lloyd, Peter Feldman
  • Patent number: 9956273
    Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: May 1, 2018
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Jennifer F. Iaci, Andrea M. Vecchione, Sarah J. Kasperbauer, Gargi Roy
  • Patent number: 9956274
    Abstract: The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: May 1, 2018
    Assignee: UCB Biopharma SPRL
    Inventor: Terence Seward Baker
  • Patent number: 9956275
    Abstract: Methods of inhibiting platelet activation and aggregation using peptide vaccine or antibodies that have binding specificity for the ? subunit of the (Na++K+)-ATPase are provided, along with methods for inhibiting or preventing thrombosis in a subject using such peptide vaccine or antibodies.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: May 1, 2018
    Inventor: Kai Yuan Xu
  • Patent number: 9956276
    Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER3 polypeptide. Methods of using the vaccine including the polynucleotide encoding the HER3 polypeptide to treat a cancer or precancer are also provided.
    Type: Grant
    Filed: January 21, 2013
    Date of Patent: May 1, 2018
    Assignee: Duke University
    Inventors: Herbert K. Lyerly, Michael A. Morse, Takuya Osada, Timothy M. Clay, Zachary C. Hartman
  • Patent number: 9956277
    Abstract: Herein a Bacillus exosporium antigen delivery (BEAD) system that provides a means to introduce recombinant proteins or small molecules into the exosporium of members of the B. cereus family of bacteria, i.e. B. anthracis, B. cereus, and B. thuringiensis, is disclosed. The system results in the surface display of recombinant proteins or small molecules such that they can stimulate an immune response. In addition, methods of making and using the system are described.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: May 1, 2018
    Assignee: The Curators of the University of Missouri
    Inventors: George C. Stewart, Brian Matthew Thompson
  • Patent number: 9956278
    Abstract: Disclosed herein are meningococcal immunogenic conjugates which can elicit immune responses against meningococcal polysaccharides (PS) from groups A, C, W-135, and Y and group B factor H binding protein (fHbp). The disclosed conjugates also exhibit bactericidal activity against meningococcal A, C, W-135, Y, B, and X serogroups. Also disclosed are improved methods for preparing conjugates, such as immunogenic conjugates, including activation of a polysaccharide with a cyanylation agent at about 4° C.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: May 1, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Che-Hung Robert Lee
  • Patent number: 9956279
    Abstract: A premixed multivalent vaccine in ready-to-use form comprising PCV2 ORF2 capsid antigen and M. hyopneumoniae antigen that reduces or prevents PCV2 infection and/or M. hyopneumoniae infection in pigs after a single dose administration of the vaccine is disclosed.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: May 1, 2018
    Assignee: Protatek International, Inc.
    Inventors: Shi Jun Ma, Jing Sui
  • Patent number: 9956280
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: May 1, 2018
    Assignee: Novavax, Inc.
    Inventors: Robin A. Robinson, Peter M. Pushko
  • Patent number: 9956281
    Abstract: The present invention is directed at a composition comprising a live swine flu virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. Preferably, the formaldehyde donor agent is selected from a non-crosslinking chemical fixative that contains urea.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: May 1, 2018
    Assignee: STRECK, INC.
    Inventors: Wayne L. Ryan, James A Grunkemeyer
  • Patent number: 9956282
    Abstract: Provided are compositions containing combinations of bacteria useful for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract, or other niche of a mammalian subject, and methods for use thereof, in particular for the treatment, inhibition, or prevention of immune disorders such as allergies and asthma.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: May 1, 2018
    Assignee: Seres Therapeutics, Inc.
    Inventors: David N. Cook, David Arthur Berry, Geoffrey von Maltzahn, Matthew R. Henn, Han Zhang, Brian Goodman
  • Patent number: 9956283
    Abstract: The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof.
    Type: Grant
    Filed: July 4, 2014
    Date of Patent: May 1, 2018
    Assignee: Arla Foods AMBA
    Inventors: Anne Staudt Kvistgaard, Peter Langborg Wejse, Sharon Donovan, Marcia H. Monaco Siegel, Sarah S. Comstock
  • Patent number: 9956284
    Abstract: The present invention relates to novel peptide compounds derived from flagellin originating from Salmonelle enterica that exhibit an in vivo immune adjuvant activity.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: May 1, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT PASTEUR DE LILLE
    Inventor: Jean-Claude Sirard
  • Patent number: 9956285
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: May 1, 2018
    Assignee: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Patent number: 9956286
    Abstract: Various embodiments of bulking or cushioning agents or material and related medical devices and methods are disclosed. For example, a method of performing a medical procedure in a tract of a body may include injecting a material in a liquid phase proximate a target site between a first tissue layer and a second tissue layer, allowing the material to transition from the liquid phase to the gel phase in response to a raise in temperature of the material to approximately at or above the predetermined temperature, and performing a surgical procedure on the target site. The material may have the liquid phase at temperatures below a predetermined temperature and a gel phase at temperatures approximately at or above the predetermined temperature.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: May 1, 2018
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Paul Scopton, Samuel Zhong, Yem Chin
  • Patent number: 9956287
    Abstract: Stabilized formulations containing a peptide, such as a glucagon, are described herein. The formulations are in the form of a solution or suspension, which exhibit little or no chemical degradation and/or aggregation of the peptide over an extended period of time. In some embodiments, the formulations are in the form of a solution containing the peptide, a solvent such as glycerin, and one or more thermal stabilizers. In other embodiments, the formulation is in the form of a suspension containing nano- and/or microparticles containing the peptide suspended in a non-aqueous, non-solvent. The nano- and/or microparticles can be prepared by micronizing the peptide with one or more humectants, such as salts, sugars, water-soluble polymers, and combinations thereof which increase the rate of dissolution of the peptide upon administration.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: May 1, 2018
    Assignee: Perosphere Inc.
    Inventors: Sasha H. Bakhru, Bryan E. Laulicht, Xuan Jiang, Lirong Chen, Solomon S. Steiner
  • Patent number: 9956288
    Abstract: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The solution is for treating a mammal suffering from one or more of pain, inflammation, fever, acute mastitis, diarrhea, lameness, locomotor deficiency, or respiratory illness.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: May 1, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Stefan Henke, Bernd Kruss, Bernhard Hassel, Hans-Juergen Kroff, Martin A. Folger, Klaus Daneck, Axel Prox
  • Patent number: 9956289
    Abstract: Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 1, 2018
    Assignee: SANTEN SAS
    Inventors: Laura Rabinovich-Guilatt, Gregory Lambert, Frederic Lallemand, Betty Philips
  • Patent number: 9956290
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of metabolic conditions. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: May 1, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9956291
    Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TR?1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TR?1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: May 1, 2018
    Inventor: Shaker A. Mousa
  • Patent number: 9956292
    Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 1, 2018
    Assignees: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Mark Pimentel, Ruchi Mathur, Steve Kanzer, Vince Wacher
  • Patent number: 9956293
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: May 1, 2018
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Patent number: 9956294
    Abstract: Disclosed are molecules for treating non-del(5q) MDS that mimic allelic deficiency in del5q MDS to sensitize the malignant clones of patient without del(5q). The disclosed molecule contains an inhibitor of Cdc25C, an inhibitor of PP2Ac?, or a combination thereof, and a toll like receptor-9 (TLR9) targeting ligand. The molecule can also contain lenalidomide, or an analogue or derivative thereof. Also disclosed is a composition comprising the disclosed molecule in a pharmaceutically acceptable carrier. Also disclosed is a method for treating non-del(5q) meylodysplastic syndrome (MDS) in a subject by administering to the subject a therapeutically effective amount of the disclosed pharmaceutical composition.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: May 1, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Alan List, Sheng Wei
  • Patent number: 9956295
    Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: May 1, 2018
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Yoram Shechter, Matityahu Fridkin, Haim Tsubery
  • Patent number: 9956296
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 1, 2018
    Assignee: INCANTHERA LTD
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Patent number: 9956297
    Abstract: Disclosed are proteasome inhibitors, fibroblast activation protein (FAP)-activated prodrugs of proteasome inhibitors, and pharmaceutically acceptable salts of the inhibitors and prodrugs. Also disclosed are related pharmaceutical compositions, and methods of using the inhibitors and prodrugs and compositions thereof, for example, in treating cancer or other cell proliferative diseases. In vitro and in vivo methods of quantifying the expression of FAP in a biopsy sample and a mammal, respectively, are also disclosed.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 1, 2018
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai, Sarah E. Poplawski
  • Patent number: 9956298
    Abstract: A compound which is selected from A: and salts and solvates thereof.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: May 1, 2018
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Arnaud Tiberghien, Thais Cailleau
  • Patent number: 9956299
    Abstract: Conjugates of specific PBD dimers with an antibody that binds to CD22, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: May 1, 2018
    Assignee: Medimmune Limited
    Inventors: Philip Wilson Howard, Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 9956300
    Abstract: The presently disclosed subject matter is directed to compositions, methods, and systems (e.g., platforms) comprising the same, the systems comprising, consisting of, or consisting essentially of micro- and macro-hydrogels that are formed from polypeptide micelles. The systems have enhanced mechanical properties that can be useful in a wide variety of applications, can be used for controlled release of drug-loaded micelles, and can be designed to reversibly assemble and disassemble on demand.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 1, 2018
    Assignee: Duke Univerity
    Inventors: Gabriel P. Lopez, Ashutosh Chilkoti, Ali Ghoorchian, Joseph R. Simon
  • Patent number: 9956301
    Abstract: The present disclosure discloses a pharmaceutical molecule of Garcinol chemically complexed with cyclodextrins and the use of the complexed molecule in prevention and management of cardiac dysfunction induced by chemotherapy, drugs and/or other insults to the heart caused by lifestyle and disease conditions. The disclosure also relates to a method of extraction and purification of high yield of 95-99% pure Garcinol from Garcinia species and a method of chemically complexing Garcinol with cyclodextrins to improve its stability and bioavailability.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: May 1, 2018
    Assignee: Indus Biotech Private Limited
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman